ASH 2021 | Assessing COVID-19 infection rates in patients with AML and MPN
Justin Ching Ting Loke
• 13 Dec 2021
Justin Ching Ting Loke, BM BCh, PhD, University of Birmingham, Birmingham, UK, describes the impact of the COVID-19 pandemic on patients with acute myeloid leukemia (AML) or high-risk myeloproliferative neoplasms (MPN). Patient data from the UK Trials Acceleration Program (TAP) revealed that patients with non-intensive treatments such as venetoclax had a lower risk of infection. Further research is required to assess vaccine efficacy in patients and the relationship between treatment patterns and infection rates. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
